(BIM) Biomerieux - Ratings and Ratios

Biomerieux SA (PA:BIM) is a global leader in the development and marketing of in vitro diagnostic solutions, primarily focused on infectious diseases. Operating across the Americas, Europe, the Middle East, Africa, and the Asia Pacific, the company provides a comprehensive suite of diagnostic tools that cater to clinical, hospital, and industrial laboratories, as well as physicians, blood banks, veterinarians, and food safety professionals. Its product portfolio includes chromogenic culture media (CHROMID RANGE), biochemical tests for carbapenemase-producing bacteria (RAPIDEC CARBA NP), and advanced systems for air, surface, and water monitoring.

The company’s diagnostic solutions extend to blood culture systems like BACT/ALERT VIRTUO and BACT/ALERT 3D, which are designed for rapid and accurate detection of microbial infections. Biomerieux also offers molecular biology solutions, including BIOFIRE multiplex PCR systems and the SPOTFIRE Lowplex PCR platform for point-of-care testing. Its mass spectrometry (VITEK MS) and automated identification and antimicrobial susceptibility testing (VITEK 2) systems are widely used in clinical settings for precise microbial identification and resistance profiling.

Biomerieux’s portfolio further includes rapid diagnostic tools such as the VITEK REVEAL system for antimicrobial susceptibility testing and the ETEST gradient method for determining antibiotic resistance. The company has also expanded into next-generation sequencing with its EPISEQ CS solution for epidemiologic monitoring. Additionally, it provides software solutions like the Biomérieux Vision Suite, which integrates data from various diagnostic platforms to support clinical decision-making.

In the food industry, Biomerieux offers solutions like the GENE-UP and VERIFLOW ranges for microbial detection. The company also provides automated sample preparation systems (ESTREAM) and nucleic acid extraction platforms (EMAG and NUCLISENS ranges). Its ARGENE Monoplex PCR tests and VIDAS B·R·A·H·M·S PCT assay for sepsis markers further complement its diagnostic offerings.

Founded in 1963 and headquartered in Marcy-lÉtoile, France, Biomerieux operates as a subsidiary of Institut Mérieux SA. The company has established itself as a key player in the biotechnology and diagnostics industry, with a market capitalization of approximately €13.8 billion. Its financial metrics, including a P/E ratio of 33.75 and a forward P/E of 24.88, reflect its position as a mature, high-growth company in the healthcare sector.